Sarepta Therapeutics has secured a license to a drug that could enable more patients to receive its gene therapies. The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in Duchenne muscular dystrophy (DMD) and limb-girdle ...
Recent Posts
- $1.9 Trillion COVID Relief Bill Passes | Who’s Eligible for Payments and How You Can Check Your Status
- New Battery Tech Helps Solve Lithium-Ion’s Biggest Problem: Degradation
- AirPods Max Update 3C39 May Address Troubling Battery Drain Issue
- This New Battery Tech Could Utilize Body Heat to Power an Apple Watch
- With Ironic Twist, Bill Gates Reveals Why He Prefers Android Over iPhone